(Q30704114)

English

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

1 reference

Europe PubMed Central

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Alzheimer's disease

1 reference

based on heuristic

inferred from title

2

object named as

Mark Oremus

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Christina Wolfson

1

object named as

Christina Wolfson

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

author name string

Vijay Shukla

3

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Franco Momoli

4

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Louise Demers

5

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Anne Perrault

6

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Yola Moride

7

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 June 2002

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

862-86; discussion 837

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

“Mini-mental state”

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Why do we need systematic overviews of randomized trials?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

How consumers and policymakers can use systematic reviews for decision making

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Agreement among reviewers of review articles

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Donepezil therapy in clinical practice: a randomized crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical global impressions in Alzheimer's clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A new rating scale for dementia syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The Global Deterioration Scale for assessment of primary degenerative dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

An economic evaluation of donepezil in the treatment of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Donepezil use in managed Medicare: effect on health care costs and utilization.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimating long-term cost savings from treatment of Alzheimer's disease. A modelling approach

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Review of outcome measurement instruments in Alzheimer's disease drug trials: introduction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of functional and quality of life scales

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of behavior and mood scales

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of global scales

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980004-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(02)80004-2

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30704114&oldid=2015658878"